Nektar Therapeutics provided earnings guidance for the year 2023. The company's GAAP revenue for full year 2023 is expected to be between $80 million and $90 million. This revenue includes $65 million to $70 million in noncash royalties and $15 million to $20 million in product sales.
Market Closed -
Other stock markets
|
Pre-market 07:05:14 | |||
1.41 USD | +10.16% | 1.43 | +1.42% |
05-09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
05-09 | Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+149.56% | 259M | |
+42.60% | 748B | |
+33.55% | 598B | |
-5.74% | 356B | |
+17.79% | 325B | |
+3.37% | 283B | |
+16.94% | 245B | |
+8.87% | 211B | |
-4.13% | 209B | |
+6.74% | 165B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Earnings Guidance for the Year 2023